close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

22.95 -0.46 (-1.97%)
Streaming Delayed Price Updated: 10:42 AM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Amgen Stock Sees Relative Strength Rating Improve To 74 ↗
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
News headline image
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study ↗
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
News headline image
Recap: Catalyst Pharmaceuticals Q3 Earnings ↗
 
Via Benzinga
News headline image
Why the growth investor may take a look at NASDAQ:CPRX. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. 
Via Investor's Business Daily
News headline image
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
News headline image
Small Caps Are On A Tear Including Speculative Biotechs ↗
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. 
Via Talk Markets
News headline image
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
News headline image
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
Catalyst Ranked #4 on the List 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Robinhood Stocks to Buy Right Now ↗
The no-cost trading platform's customers have their clear favorites, and they're more mainstream names than you might expect them to be. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalyst's Chairman 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Robinhood Stocks With Market-Beating Potential ↗
These diamonds in the rough won't stay down. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Best Defensive Stocks To Invest In 2023 ↗
A defensive stock is a stock that demonstrates relatively stable performance regardless of the current state of the economy. Defensive stocks are less prone to the economic cycle of expansions and... 
Via Talk Markets
Topics Economy
News headline image
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+ ↗
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today